APUS

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.50	Insider Own	75.22%	Shs Outstand	12.58M	Perf Week	-52.67%
Market Cap	17.86M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.12M	Perf Month	-24.47%
Enterprise Value	14.05M	PEG	-	EPS next Q	-	Inst Own	3.66%	Short Float	2.98%	Perf Quarter	-90.72%
Income	-6.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.43	Perf Half Y	-93.63%
Sales	0.00M	P/B	0.12	EPS next Y	-	ROA	-7.31%	Short Interest	0.09M	Perf YTD	-91.34%
Book/sh	12.19	P/C	1.53	EPS next 5Y	-	ROE	-7.90%	52W High	40.31 -96.48%	Perf Year	-92.15%
Cash/sh	0.93	P/FCF	-	EPS past 3/5Y	-108.43% -	ROIC	-3.91%	52W Low	1.34 5.97%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	61.21% 27.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-344.53%	Oper. Margin	-	ATR (14)	1.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	29.39	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	1.31	EPS Q/Q	-245.49%	SMA20	-56.73%	Beta	4.92	Target Price	-
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-85.58%	Rel Volume	0.11	Prev Close	1.46
Employees	7	LT Debt/Eq	0.00	Earnings	-	SMA200	-91.73%	Avg Volume	214.95K	Price	1.42
IPO	May 09, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,497	Change	-2.74%

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your Finviz experience